KR20160131119A - TrkA 키나제 억제제, 조성물 및 그의 방법 - Google Patents

TrkA 키나제 억제제, 조성물 및 그의 방법 Download PDF

Info

Publication number
KR20160131119A
KR20160131119A KR1020167029497A KR20167029497A KR20160131119A KR 20160131119 A KR20160131119 A KR 20160131119A KR 1020167029497 A KR1020167029497 A KR 1020167029497A KR 20167029497 A KR20167029497 A KR 20167029497A KR 20160131119 A KR20160131119 A KR 20160131119A
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
alkyl
methyl
benzamide
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167029497A
Other languages
English (en)
Korean (ko)
Inventor
헬렌 미첼
마크 이. 프랠리
앤드류 제이. 쿡
크레이그 에이. 스텀프
이 헝 첸
더글라스 씨. 비쇼어
쉬-팡 장
케이시 씨. 맥코마스
캐시 쉬리파
멜로디 맥워터
스와티 피. 머서
키이스 피. 무어
핑 리우
해롤드 비. 우드
춘 싱 리
칭후아 마오
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20160131119A publication Critical patent/KR20160131119A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020167029497A 2014-03-26 2015-03-23 TrkA 키나제 억제제, 조성물 및 그의 방법 Withdrawn KR20160131119A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/074143 2014-03-26
PCT/CN2014/074143 WO2015143652A1 (en) 2014-03-26 2014-03-26 TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
PCT/US2015/022004 WO2015148373A2 (en) 2014-03-26 2015-03-23 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Publications (1)

Publication Number Publication Date
KR20160131119A true KR20160131119A (ko) 2016-11-15

Family

ID=54193893

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167029497A Withdrawn KR20160131119A (ko) 2014-03-26 2015-03-23 TrkA 키나제 억제제, 조성물 및 그의 방법
KR1020167029495A Withdrawn KR20160132114A (ko) 2014-03-26 2015-03-23 TrkA 키나제 억제제, 조성물 및 그의 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167029495A Withdrawn KR20160132114A (ko) 2014-03-26 2015-03-23 TrkA 키나제 억제제, 조성물 및 그의 방법

Country Status (10)

Country Link
US (2) US9862707B2 (enExample)
EP (2) EP3122345B1 (enExample)
JP (2) JP2017512786A (enExample)
KR (2) KR20160131119A (enExample)
CN (2) CN106456582A (enExample)
AU (2) AU2015236438A1 (enExample)
CA (2) CA2942817A1 (enExample)
MX (2) MX2016012483A (enExample)
RU (2) RU2016141645A (enExample)
WO (3) WO2015143652A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418615B (zh) * 2015-12-09 2018-02-02 北京工业大学 苯甲酰胺衍生物及制备和应用
US11701345B2 (en) 2017-06-19 2023-07-18 University Of Maryland, Baltimore Car activator agents for cyclophosphamide-based treatments of cancer
EP3692052A4 (en) * 2017-10-04 2021-03-17 Dana Farber Cancer Institute, Inc. INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111819179B (zh) * 2017-12-15 2023-09-01 金字塔生物科技公司 用于治疗癌症的作为trk激酶抑制剂的相关化合物
CA3096746A1 (en) 2018-04-12 2019-10-17 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
AU2019323446B2 (en) * 2018-08-22 2025-01-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN111269233A (zh) * 2018-12-05 2020-06-12 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
PH12022550874A1 (en) 2019-10-09 2023-03-27 Bayer Ag Novel heteroaryl-triazole compounds as pesticides
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
TW202134226A (zh) 2019-11-18 2021-09-16 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3173262A1 (en) 2020-02-26 2021-09-02 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
CN113666862B (zh) * 2021-08-18 2024-05-31 山东大学 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB599834A (en) * 1943-04-08 1948-03-22 Francolor Sa Improvements in or relating to the manufacture of azodyestuffs
DK0714898T3 (da) * 1994-06-21 2002-03-18 Otsuka Pharma Co Ltd Pyrazolo[1,5-a]primidinderivat
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE19946322A1 (de) 1999-09-28 2001-03-29 Bayer Ag Verfahren zur Konditionierung von Ionenaustauscherharzen
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU4878601A (en) * 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
KR100713137B1 (ko) * 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
CZ2004359A3 (cs) * 2001-09-26 2004-09-15 Pharmacia Italia S.P.A. Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
US20030144518A1 (en) * 2001-12-07 2003-07-31 The Procter & Gamble Company Process for preparing 3-acylamino-imidazo[1,2-a]pyridines
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EA011479B1 (ru) 2002-12-24 2009-04-28 Ринат Ньюросайенс Корп. Антитело связывающееся с ngf, и способы его применения
UA81668C2 (en) 2003-05-01 2008-01-25 Бристол-Майерс Сквибб Компани Normal;heading 1;heading 2;ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
TWI382031B (zh) 2003-07-15 2013-01-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
EP1667983A4 (en) 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP1720855A4 (en) * 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
JP2008540335A (ja) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
NZ564317A (en) 2005-05-16 2011-01-28 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2009511529A (ja) 2005-10-13 2009-03-19 デブジェン エヌブイ キナーゼ阻害剤
US20090163549A1 (en) 2005-12-15 2009-06-25 Hiroyuki Kai Pharmaceutical Composition Comprising an Amide Derivative
MX2008015457A (es) 2006-07-07 2009-01-16 Boehringer Ingelheim Int Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales.
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
AU2008262038A1 (en) * 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
US20100240657A1 (en) 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
KR101567763B1 (ko) * 2007-07-20 2015-11-12 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 활성인 치환된 인다졸 유도체
CA2701839A1 (en) 2007-10-09 2009-04-16 Merck Patent Gmbh N- (pyrazole-3-yl) -benzamide derivatives as glucokinase activators
DK2350075T3 (da) * 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
KR101048448B1 (ko) * 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
EP2459184A1 (en) * 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CN110483499A (zh) * 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
WO2012003387A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
CN103168032A (zh) * 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
UA109150C2 (xx) 2010-09-01 2015-07-27 Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів
WO2012044090A2 (ko) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
US9079859B2 (en) 2011-01-21 2015-07-14 Auckland Uniservices Limited Synthetic lethal targeting of glucose transport
BR112013020213A2 (pt) 2011-02-09 2016-08-02 Syngenta Participations Ag compostos inseticidas
ES2615738T3 (es) 2011-05-13 2017-06-08 Array Biopharma, Inc. Compuestos de pirrolidinil urea, pirrolidinil tiourea y pirrolidinil guanidina como inhibidores de trkA quinasa
BR112013029999B1 (pt) 2011-05-23 2021-03-02 Merck Patent Gmbh derivados de tiazol, e medicamento
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013009582A1 (en) * 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CA2854936A1 (en) * 2011-11-14 2013-05-23 Tesaro, Inc. Modulating certain tyrosine kinases
EP2791138B1 (en) * 2011-12-12 2018-06-06 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑

Also Published As

Publication number Publication date
JP2017512786A (ja) 2017-05-25
WO2015143652A1 (en) 2015-10-01
CA2942957A1 (en) 2015-10-01
RU2016141647A (ru) 2018-04-27
WO2015148354A2 (en) 2015-10-01
US20170114056A1 (en) 2017-04-27
AU2015236363A1 (en) 2016-09-01
WO2015148373A3 (en) 2015-11-26
EP3122344A2 (en) 2017-02-01
MX2016012481A (es) 2016-12-16
EP3122345B1 (en) 2020-12-16
US9862707B2 (en) 2018-01-09
RU2016141645A (ru) 2018-04-27
EP3122345A4 (en) 2017-10-04
MX2016012483A (es) 2016-12-16
US20170107204A1 (en) 2017-04-20
AU2015236438A1 (en) 2016-09-01
EP3122344B1 (en) 2022-04-27
US9862716B2 (en) 2018-01-09
WO2015148354A3 (en) 2015-12-03
RU2016141645A3 (enExample) 2018-10-26
EP3122345A2 (en) 2017-02-01
JP2017508766A (ja) 2017-03-30
WO2015143652A8 (en) 2015-12-10
CN106456582A (zh) 2017-02-22
CN106456581A (zh) 2017-02-22
CA2942817A1 (en) 2015-10-01
RU2016141647A3 (enExample) 2018-06-26
WO2015148373A2 (en) 2015-10-01
EP3122344A4 (en) 2017-09-06
KR20160132114A (ko) 2016-11-16

Similar Documents

Publication Publication Date Title
EP3122345B1 (en) Trka kinase inhibitors, compositions and methods thereof
RU2672583C2 (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
US9914736B2 (en) TrKA kinase inhibitors, compositions and methods thereof
WO2015039333A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10556900B2 (en) TrkA kinase inhibitors, compositions and methods thereof
WO2016054807A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP2731439A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TW202214634A (zh) 雜環化合物及其衍生物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161021

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination